Free Trial

HEALTHCARE: Roche (ROSW: Aa2/AA/AA): Poseida Acquisition

HEALTHCARE

Not a spread mover

  • Roche to acquire Poseida Therapeutics in a $1.5bn deal
  • Gives Roche access to CAR-T therapies and genetic medicines
  • Roche has CHF14bn FCF per year
25 words

To read the full story

Close

Why MNI

MNI is the leading provider

of intelligence and analysis on the Global Fixed Income, Foreign Exchange and Energy markets. We use an innovative combination of real-time analysis, deep fundamental research and journalism to provide unique and actionable insights for traders and investors. Our "All signal, no noise" approach drives an intelligence service that is succinct and timely, which is highly regarded by our time constrained client base.

Our Head Office is in London with offices in Chicago, Washington and Beijing, as well as an on the ground presence in other major financial centres across the world.

Not a spread mover

  • Roche to acquire Poseida Therapeutics in a $1.5bn deal
  • Gives Roche access to CAR-T therapies and genetic medicines
  • Roche has CHF14bn FCF per year